Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

Biosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Truxima rival at a 10% discount following FDA approval. Truxima – originally ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), a China ...

Specifically, we still consider its core assets Tyvyt, a PD-1 inhibitor, and three biosimilars of bevacizumab (Avastin), adalimumab (Humira), and rituximab (Rituxan) as the near-term growth drivers.

It includes Avastin, Herceptin, and Rituxan, which are declining franchises due to loss of exclusivity and biosimilar threats, and Tecentriq, which is Roche’s blockbuster PD-L1 inhibitor that is ...

Breaking Science Session at the 2025 American Academy of Neurology (AAN) meeting, Remegen announced exciting results from a ...

To date, the company’s launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), a ...

Henlius (2696) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the ...

An In-depth Market Research ReportThe Cancer Biologics Market is one of the fastest-growing segments within the global ...